Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all
Page 1
Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.
Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet L, Escoffre-Barbe M, Mariette S, Benboubker L, Caillot D, Sonntag C, Touzeau C, Dupuis J, Moreau P, Leleu X, Facon T, Hébraud B, Corre J, Attal M. Roussel M, et al. Blood. 2021 Apr 7:blood.2021010744. doi: 10.1182/blood.2021010744. Online ahead of print. Blood. 2021. PMID: 33827114
Post-Discharge Thromboembolic Outcomes and Mortality of Hospitalized COVID-19 Patients: The CORE-19 Registry.
Giannis D, Allen S, Tsang J, Flint S, Pinhasov T, Williams S, Tan G, Thakur R, Leung C, Snyder MS, Bhatia C, Garrett D, Cotte C, Isaacs S, Gugerty E, Davidson A, Marder GS, Schnitzer A, Goldberg B, McGinn T, Davidson K, Barish MA, Qiu M, Zhang M, Goldin M, Matsagkas M, Arnaoutoglou EM, Spyropoulos AC, Northwell Health CC. Giannis D, et al. Blood. 2021 Apr 6:blood.2020010529. doi: 10.1182/blood.2020010529. Online ahead of print. Blood. 2021. PMID: 33824972
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park J, Abedi M, Castro J, DeAngelo DJ, Malone AK, Mawad R, Schiller G, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. Shah BD, et al. Blood. 2021 Apr 7:blood.2020009098. doi: 10.1182/blood.2020009098. Online ahead of print. Blood. 2021. PMID: 33827116
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani R, et al. Blood. 2021 Apr 7:blood.2020009178. doi: 10.1182/blood.2020009178. Online ahead of print. Blood. 2021. PMID: 33827139
A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatures were consistent with an activated T-cell response. ...
A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatur …
Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R, Diepstraten ST, Moujalled DM, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljic B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley TD, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly G, Wei AH. Thijssen R, et al. Blood. 2021 Apr 6:blood.2020010167. doi: 10.1182/blood.2020010167. Online ahead of print. Blood. 2021. PMID: 33824975
Therefore, targeting these pro-survival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL2 has produced clinically relevant responses in blood cancers with aberrant TP53. ...
Therefore, targeting these pro-survival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation …
Acquired platelet GPVI receptor dysfunction in critically-ill patients with sepsis.
Weiss LJ, Manukjan G, Pflug A, Winter N, Weigel ML, Nagler N, Kredel M, Lam TT, Nieswandt B, Weismann D, Schulze H. Weiss LJ, et al. Blood. 2021 Apr 7:blood.2020009774. doi: 10.1182/blood.2020009774. Online ahead of print. Blood. 2021. PMID: 33827131
GPVI deficiency was in part inducible in platelets of healthy donors through co-incubation in whole blood, but not in plasma from sepsis patients. Platelet aggregation upon GPVI stimulation increased only in those patients whose condition ameliorated. ...
GPVI deficiency was in part inducible in platelets of healthy donors through co-incubation in whole blood, but not in plasma from sep …
CD27 is required for protective lytic EBV antigen specific CD8+ T cell expansion.
Deng Y, Chatterjee B, Zens K, Zdimerova H, Muller A, Schuhmachers P, Ligeon LA, Bongiovanni A, Capaul R, Zbinden A, Holler A, Stauss HJ, Hammerschmidt W, Münz C. Deng Y, et al. Blood. 2021 Apr 7:blood.2020009482. doi: 10.1182/blood.2020009482. Online ahead of print. Blood. 2021. PMID: 33827115